PMID- 32420356
OWN - NLM
STAT- MEDLINE
DCOM- 20210318
LR  - 20210318
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Resveratrol Attenuates High Glucose-Induced Vascular Endothelial Cell Injury by 
      Activating the E2F3 Pathway.
PG  - 6173618
LID - 10.1155/2020/6173618 [doi]
LID - 6173618
AB  - Type 2 diabetes mellitus (T2DM) is the most common metabolic disease. High 
      glucose-induced macrovascular disease and microangiopathy are major complications 
      of diabetes. E2F3, a member of the E2F transcription factor family, is closely 
      related to cardiovascular diseases. Resveratrol, a nonflavonoid polyphenolic 
      compound widely found in plants, has been shown to have cardiovascular 
      protection. However, there are few studies on whether resveratrol can effectively 
      treat diabetic angiopathy, and the specific mechanism involved needs further 
      study. This study investigated whether E2F3 transcription factors are involved in 
      the process of vascular endothelial injury induced by high glucose and observed 
      its effects on the proliferation of vascular endothelial cells. Then, it analyzed 
      whether resveratrol can inhibit high glucose-induced vascular endothelial cell 
      injury by regulating the E2F3 pathway. We demonstrated that the expression level 
      of the E2F3 transcription factor was significantly inhibited in high glucose 
      state. Resveratrol inhibited high glucose-induced vascular endothelial cell 
      injury by upregulating the E2F3 pathway. High glucose can induce vascular 
      endothelial injury by inhibiting E2F3 gene expression, while resveratrol can 
      inhibit high glucose-induced vascular endothelial injury by activating the E2F3 
      pathway.
CI  - Copyright (c) 2020 Xiaolian Ding et al.
FAU - Ding, Xiaolian
AU  - Ding X
AD  - Department of Nephrology and Endocrinology, Weinan Central Hospital of Weinan, 
      Shaanxi Province, China 714000.
FAU - Yao, Wei
AU  - Yao W
AD  - Department of Endocrinology, Shanghai University of Medicine & Health Sciences, 
      Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New District, 
      Shanghai, China 201318.
FAU - Zhu, Jie
AU  - Zhu J
AD  - Department of Endocrinology, Shanghai University of Medicine & Health Sciences, 
      Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New District, 
      Shanghai, China 201318.
FAU - Mu, Kaida
AU  - Mu K
AD  - Department of Endocrinology, Shanghai University of Medicine & Health Sciences, 
      Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New District, 
      Shanghai, China 201318.
FAU - Zhang, Jing
AU  - Zhang J
AUID- ORCID: 0000-0003-4805-5935
AD  - Department of Endocrinology, Shanghai University of Medicine & Health Sciences, 
      Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New District, 
      Shanghai, China 201318.
FAU - Zhang, Jin-An
AU  - Zhang JA
AUID- ORCID: 0000-0002-1700-4695
AD  - Department of Endocrinology, Shanghai University of Medicine & Health Sciences, 
      Affiliated Zhoupu Hospital, No. 1500 Zhouyuan Road, Pudong New District, 
      Shanghai, China 201318.
LA  - eng
PT  - Journal Article
DEP - 20200428
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (E2F3 Transcription Factor)
RN  - IY9XDZ35W2 (Glucose)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Cell Proliferation/drug effects
MH  - Cell Shape/drug effects
MH  - Cells, Cultured
MH  - *E2F3 Transcription Factor/analysis/genetics/metabolism
MH  - Glucose/*adverse effects
MH  - Human Umbilical Vein Endothelial Cells/*drug effects
MH  - Humans
MH  - Resveratrol/*pharmacology
MH  - Up-Regulation/*drug effects
PMC - PMC7204347
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/19 06:00
MHDA- 2021/03/19 06:00
PMCR- 2020/04/28
CRDT- 2020/05/19 06:00
PHST- 2019/11/30 00:00 [received]
PHST- 2020/03/21 00:00 [revised]
PHST- 2020/04/10 00:00 [accepted]
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2021/03/19 06:00 [medline]
PHST- 2020/04/28 00:00 [pmc-release]
AID - 10.1155/2020/6173618 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Apr 28;2020:6173618. doi: 10.1155/2020/6173618. eCollection 
      2020.